PB2099: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-1607, A FIRST-IN-CLASS ORAL CBL-B INHIBITOR, IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING RICHTER TRANSFORMATION DLBCL
Adam Sharp(Institute of Cancer Research), Hendrick-Tobias Arkenau(Sarah Cannon Research Institute), Sarah Whelan(Nurix (United States)), A. Williams(Sarah Cannon Research Institute), Sarah P. Blagden(Churchill Hospital), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Srinand Nandakumar(Nurix (United States)), R. Plummer(Northern Health and Social Care Trust), Matthew Krebs(Christie's), Daniel Hochhauser(Royal London Hospital), Jennifer Mary Evans(University of Glasgow), Francesco Basile(Nurix (United States)), S. Rogers(Nurix (United States)), K. Jameson, Simon Pacey(Royal Marsden NHS Foundation Trust)
Cited by 5
Related Papers
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k